At 48 h following TPL treatment, a Cell Counting kit‑8 study was performed and the IC50 value was determined at 101.55☒.45 ng/ml. TPL treatment significantly inhibited BMMSC proliferation compared with the untreated control (P<0.05). ELISA was applied to measure vascular endothelial growth factor (VEGF) levels in the supernatant of the cultured and treated BMMSCs.
Reverse transcription‑quantitative polymerase chain reaction assays were applied to measure interleukin (IL)‑6, IL‑1β and stem cell factor (SCF or Kit ligand) mRNA expression and western blot assays were performed to analyze transcription factor p65 (P65) expression in TPL‑treated BMMSCs. Cell Counting kit‑8 assays were performed to assess proliferation activity and flow cytometry with Annexin V‑fluorescein/propidium iodide was used to detect cell apoptosis of TPL‑treated BMMSCs. Thalidomide is currently used as a positive control drug in the treatment of MM.
In the current study, bone marrow‑derived mesenchymal stem cells (BMMSCs) from patients with MM were isolated and treated with TPL at varying concentrations.
Only few studies have focused on TPL as a potential treatment in multiple myeloma (MM). Its antiproliferative effects are well established. Triptolide (TPL), an extract of the Chinese herb Tripterygium wilfordii Hook F, is a potent anti‑inflammatory agent that further possesses anticancer activity.
0 kommentar(er)
